Novartis
Novartis sheds blood diagnostics for $1.7 billion
November 11, 2013Sales and Marketing Genoptix, Novartis, blood, grifols
Novartis has announced the sale of its blood transfusion diagnostics unit to the specialist Spanish firm Grifols for $1.67 billion.Headquartered …
NICE ‘yes’ to Lucentis – with price cut
October 25, 2013Sales and Marketing Dillon, Lucentis, NICE, Novartis
A price cut is the deal-breaking condition attached to NICE’s final draft guidance recommending Lucentis as an option for patients …
Novartis sees profit slip
October 23, 2013Sales and Marketing Afinitor, Diovan, Novartis, Q3, gilenya
Novartis saw generic competition erode profit in the third quarter of the year, although sales across the group actually rose …
Roche rules out merger talk
October 18, 2013Sales and Marketing Cancer, Herceptin, Novartis, Roche, merger
Roche has dismissed talk of merging with fellow Swiss manufacturer Novartis as it revealed its results for the last three …
Novartis launches Facebook ‘retina app’
October 15, 2013Medical Communications AMD, Bayer, Lucentis, Novartis, set your sights
Novartis, the world’s biggest eye-care drugmaker, has launched a new Facebook retina app to raise awareness of retinal disease. The …
Novartis ‘sorry’ for Diovan data
September 27, 2013Sales and Marketing Japan, Novartis, diovan data
Novartis has apologised to patients in Japan over the alleged manipulation of data in five trials of its blockbuster blood …
Novartis backs new anti-malaria campaign
September 23, 2013Medical Communications, Sales and Marketing Novartis, donation, malaria
Novartis launches China investigation
September 18, 2013Medical Communications, Sales and Marketing Alcon, China, Novartis, corrpution
Novartis signs Regenerex deal
September 9, 2013Sales and Marketing CLL, Novartis, kidney, regenerex
Novartis has signed a deal with US biopharma firm Regenerex to use its novel stem cell-based platform, which may have …
Amgen/Cytokinetics heart drug fails in clinical trial
September 3, 2013Research and Development, Sales and Marketing Amgen, Novartis, cytokinetics, omecamtiv mecarbil
A new heart failure drug by Amgen and Cytokinetics has fallen short of its primary endpoint in a Phase II …
Eylea receives new European approval
August 30, 2013Research and Development, Sales and Marketing Bayer, CRVO, Eylea, Lucentis, Novartis, wet AMD
ThromboGenics/Novartis’ Jetrea gains NICE ‘yes’
August 30, 2013Alcon, Jetrea, NICE, Novartis, ThromboGenics
Latest content
FibroFind appoints Lee Borthwick as CEO
